iclepertin

News

Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.

News

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.